Genmab, GSK report updated ofatumumab data

Genmab A/S (CSE:GEN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reported updated data late Monday from a Phase III trial of ofatumumab to treat refractory chronic lymphocytic leukemia (CLL). The human mAb against CD20 produced an objective response rate (ORR) of 51% in 95 patients refractory to fludarabine or alemtuzumab. Genmab said the data from the completed trial are consistent with efficacy and safety data reported in a 2008 interim analysis, which formed the basis for FDA's accelerated approval last year for the drug to treat CLL refractory to fludarabine and alemtuzumab. In the interim analysis, ofatumumab produced an ORR of 51% in 59 patients, which met the primary endpoint. Genmab was up DKK1.05 to DKK63.05 on Monday. ...